RxDoctor Payments Data

Paul Igbide

Psychiatric/Mental Health · West Hempstead, NYNPI 1912263831

Payments from drug & device makers

$2,210in general payments, 2019–2025

Across 85 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$423
  • Lilly USA, LLC$319
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$289
  • AstraZeneca$204
  • Philips North America LLC$194
  • Otsuka America Pharmaceutical, Inc.$136
  • plus $645 from 14 others

What the payments were for

  • Food & beverage$2,16498%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,210 in reported general payments places this provider in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$49,012
Medicare patients
95
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$63,893
JardianceEmpagliflozin27$31,755
TrulicityDulaglutide15$15,858
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,136
Metformin Hcl12$4,068
Atorvastatin Calcium74$697
Alcohol Prep PadsAlcohol Antiseptic Pads27$428
Albuterol Sulfate HfaAlbuterol Sulfate12$359
Bupropion Hcl SrBupropion Hcl15$332
Losartan Potassium21$272
Amlodipine Besylate43$259
Enalapril Maleate16$220
Metoprolol Succinate16$193
Duloxetine Hcl11$173
Omeprazole21$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$319$79,75171 claims
Boehringer IngelheimJardiance$96$31,75527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in West Hempstead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →